ir.archtherapeutics.com ir.archtherapeutics.com

ir.archtherapeutics.com

Overview :: Arch Therapeutics, Inc. (ARTH)

View our latest Corporate Presentation. Go to Detailed Stock Info ›. Arch Therapeutics Announces Private Placement. Arch Therapeutics Obtains Additional Safety Data for Its AC5 Surgical Hemostatic Device(TM) in Successful Preclinical Toxicity Test. Arch Therapeutics Initiates Research and Development Collaboration With CURAM Centre for Research in Medical Devices. Go to Press Releases ›. Visit our FAQs for commonly asked questions and answers. 1859 Whitney Mesa Dr. Henderson, NV 89014.

http://ir.archtherapeutics.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR IR.ARCHTHERAPEUTICS.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

December

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Tuesday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 4.6 out of 5 with 11 reviews
5 star
7
4 star
4
3 star
0
2 star
0
1 star
0

Hey there! Start your review of ir.archtherapeutics.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

0.2 seconds

CONTACTS AT IR.ARCHTHERAPEUTICS.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Overview :: Arch Therapeutics, Inc. (ARTH) | ir.archtherapeutics.com Reviews
<META>
DESCRIPTION
View our latest Corporate Presentation. Go to Detailed Stock Info ›. Arch Therapeutics Announces Private Placement. Arch Therapeutics Obtains Additional Safety Data for Its AC5 Surgical Hemostatic Device(TM) in Successful Preclinical Toxicity Test. Arch Therapeutics Initiates Research and Development Collaboration With CURAM Centre for Research in Medical Devices. Go to Press Releases ›. Visit our FAQs for commonly asked questions and answers. 1859 Whitney Mesa Dr. Henderson, NV 89014.
<META>
KEYWORDS
1 overview
2 corporate mission
3 leadership
4 advisors
5 market
6 market scope
7 existing treatments
8 technology
9 concept
10 manufacturing
CONTENT
Page content here
KEYWORDS ON
PAGE
overview,corporate mission,leadership,advisors,market,market scope,existing treatments,technology,concept,manufacturing,milestones,product,development,news,press releases,in the news,presentations,investors,investor relations,ir overview,news / events
SERVER
Apache/2.4.12 (Ubuntu)
POWERED BY
PHP/5.5.9-1ubuntu4.11
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Overview :: Arch Therapeutics, Inc. (ARTH) | ir.archtherapeutics.com Reviews

https://ir.archtherapeutics.com

View our latest Corporate Presentation. Go to Detailed Stock Info ›. Arch Therapeutics Announces Private Placement. Arch Therapeutics Obtains Additional Safety Data for Its AC5 Surgical Hemostatic Device(TM) in Successful Preclinical Toxicity Test. Arch Therapeutics Initiates Research and Development Collaboration With CURAM Centre for Research in Medical Devices. Go to Press Releases ›. Visit our FAQs for commonly asked questions and answers. 1859 Whitney Mesa Dr. Henderson, NV 89014.

INTERNAL PAGES

ir.archtherapeutics.com ir.archtherapeutics.com
1

Email Alerts :: Arch Therapeutics, Inc. (ARTH)

http://ir.archtherapeutics.com/email-alerts

Please fill out the form below to receive company press releases and SEC filings via email when they occur. Annual & Quarterly Reports. We respect your privacy. We do not sell, rent, or loan any information to any third party. Any information you give us is held with the utmost care and security, and will be used only in ways to which you have consented.

2

Press Releases :: Arch Therapeutics, Inc. (ARTH)

http://ir.archtherapeutics.com/press-releases/detail/450/arch-therapeutics-announces-private-placement

Arch Therapeutics Announces Private Placement. 30 Million in Net Proceeds Expected. FRAMINGHAM, MA - (Marketwired) - 07/01/15 - Arch Therapeutics, Inc. (OTCQB: ARTH) (". Developer of the AC5 Surgical Hemostatic Device™ (". Is pleased to announce that it raised $3,066,000 in equity financing in a private placement to 19 accredited investors (the ". On June 30, 2015 (the ". And anticipates raising up to an additional $100,000 before concluding the private placement (the ". 2015 Private Placement Financing.

3

Press Releases :: Arch Therapeutics, Inc. (ARTH)

http://ir.archtherapeutics.com/press-releases

Arch Therapeutics Reports AC5 Topical Hemostatic Device Successfully Stopped Bleeding in Patients on Antiplatelet Therapy in Recently Completed Clinical Study. Arch Therapeutics Will Present at the 2016 Bio Investor Forum in San Francisco, California October 18-19th, 2016. Arch Therapeutics Will Present at the 2016 Aegis Capital Growth Conference in Las Vegas, NV September 20-22, 2016. Arch Therapeutics Provides Corporate Update at the 18th Annual Rodman and Renshaw Global Investment Conference.

4

Media :: Arch Therapeutics, Inc. (ARTH)

http://ir.archtherapeutics.com/media/view/14/dr-terrence-norchi-interviewed-on-your-familys-health

Radio Interview of Dr. Norchi by Professor Joan Buckley of "Your Family's Health" (30 Minutes). Sign up for email alerts. Be the first to receive breaking news.

5

IR Calendar :: Arch Therapeutics, Inc. (ARTH)

http://ir.archtherapeutics.com/ir-calendar

There are no upcoming events scheduled at this time. Sign up here. To receive notices about upcoming events and press releases. 05/5/16 4:30 pm ET. PIONEERS 2016, hosted by Joseph Gunnar and Co. 03/15/16 5:30 pm PT. 28th Annual ROTH Conference. The Ritz-Carlton Laguna Niguel, Dana Point, CA. 02/22/16 1:00 PM ET. SeeThruEquity 2nd Annual Innovations Investor Conference. The Ritz-Carlton South Beach, Miami, Florida. Sign up for email alerts. Be the first to receive breaking news.

UPGRADE TO PREMIUM TO VIEW 1 MORE

TOTAL PAGES IN THIS WEBSITE

6

SOCIAL ENGAGEMENT



OTHER SITES

ir.aqr.com ir.aqr.com

AQR Capital - Investor Relations - Overview

Investor and Media Contact. There are currently no news releases. Primary IR and Media Contact. Quotes delayed at least 15 minutes. Market data provided by Interactive Data. Powered and implemented by Interactive Data Managed Solutions.

ir.aquaamerica.com ir.aquaamerica.com

Investor Relations | Aqua America

Skip to main navigation. Reconciliation of GAAP to Non-GAAP Financial Measures. Regulated segment - Efficiency ratio adjusted for purchased water. Reconciliation of GAAP to Non-GAAP financial measures - EBITDA reconciliation for continuing operations. Adjusted Net Income EPS Q4 2017. Dividend Reinvestment and DSPP. There are currently no events to display. Feb 27, 2018. Aqua America Reports Earnings for 2017, Announces 2018 Guidance. Feb 5, 2018. Aqua America Declares March 2018 Dividend. Feb 1, 2018.

ir.arafaholding.com ir.arafaholding.com

Arafa Holding | Investor Relations

Board and Shareholders Actions. Share and Corporate Information. Luxury, Formal and Casual Wear across own brands. Textiles, Apparel and Tailoring, Retail and Distribution. Concrete, with 47 retail stores nationwide across Egypt. Learn about Arafa Holding's business model, strategy, brands and partnerships through our downloadable presentations in the Presentations and Publications center. As of 16:02, on Thu, Aug, 13 2015. Arafa Earnings Release 1Q2015. Arafa Holding Financials 1Q2015 (Arabic).

ir.arcadis.com ir.arcadis.com

Arcadis Investors - ARCADIS NV - Investor Relations

United Kingdom (ARCADIS AYH). ARCADIS at a Glance. Reasons to invest in ARCADIS. Share Quote and Chart. Risk and Risk Management. IR Team and Subscriptions. To opt-in to receive our quarterly retail investor newsletter. ARCADIS Q2 2015 Results. Jul 29, 2015 at 3:00 PM CET. Tetra Tech, Inc. 07 Aug 2015 latest: 17:35 CET. Euro; 22.38. Amounts in € millions unless otherwise stated. Organic gross revenue growth. Organic net revenue growth. Net income per share (in €). Net income from operations.

ir.archcapgroup.com ir.archcapgroup.com

Arch > Investor Information

Earnings Releases and Supplements. Non-US. Subsidiary Information. 07/30/2015 11:00 AM ET. Q2 2015 Arch Capital Group Earnings Conference Call. As of August 14, 2015 -. Minimum 20 minute delay. Q2 2015 Arch Capital Group Earnings Conference Call. Thursday, July 30, 2015. We seek to increase shareholder value through three main strategic principles:. Selectively pursue diverse specialty markets where we can apply our knowledge and expertise;. Maintain a disciplined underwriting approach to enable us to se...

ir.archtherapeutics.com ir.archtherapeutics.com

Overview :: Arch Therapeutics, Inc. (ARTH)

View our latest Corporate Presentation. Go to Detailed Stock Info ›. Arch Therapeutics Announces Private Placement. Arch Therapeutics Obtains Additional Safety Data for Its AC5 Surgical Hemostatic Device(TM) in Successful Preclinical Toxicity Test. Arch Therapeutics Initiates Research and Development Collaboration With CURAM Centre for Research in Medical Devices. Go to Press Releases ›. Visit our FAQs for commonly asked questions and answers. 1859 Whitney Mesa Dr. Henderson, NV 89014.

ir.arctreit.com ir.arctreit.com

ARCTREIT.COM

ir.ardelyx.com ir.ardelyx.com

Investor Relations - Ardelyx

Non-Systemic Therapies, Reduced Risk. Annual Reports and Proxies. We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Ardelyxs financial performance into perspective. 070 ( 3.84%). 4:00 PM ET on August 14, 2015. Delayed at least 20 minutes. August 12, 2015. Ardelyx Reports Second Quarter 2015 Financial Results. August 5, 2015. Ardelyx to Report Second Quarter 2015 Financial Results on August 12, 2015.

ir.argostherapeutics.com ir.argostherapeutics.com

Investors – Argos Therapeutics

Platform & Pipeline. Platform & Pipeline. Aug 14, 2015 at 4:00 PM ET. Intraday data provided by eSignal. Press Releases View all. Argos Therapeutics Reports Second Quarter 2015 Financial Results and Operational Highlights. Argos Therapeutics Announces Pilot Clinical Trial of AGS-003 as Neoadjuvant Immunotherapy for Localized Renal Cell Carcinoma. Events and Presentations View all. May 14, 2015 at 4:30 PM ET. Argos Therapeutics, Inc. First Quarter 2015 Financial Results Conference Call.

ir.arm.com ir.arm.com

ARM Holdings - Investor Relations - ARM Holdings plc - ARM Holdings plc - Investors

This site uses cookies to store information on your computer. By continuing to use our site, you consent to our cookies. PLEASE NOTE: If you have adjusted your cookie settings on www.arm.com. These settings do not apply to this website. ARM websites use two types of cookie: ( 1). Those that enable the site to function and perform as required; and (2). To learn how they can be disabled. By disabling cookies some features of the site will not work. Accept and hide this message. Mali Cost Efficient Graphics.

ir.armadahoffler.com ir.armadahoffler.com

IR Overview | Armada

Back to the Corporate Site. Armada Hoffler Properties to Discuss Fourth Quarter Earnings on February 9th. Armada Hoffler Properties Announces Retail Acquisitions in North Carolina and Virginia. Armada Hoffler Properties Added to the MSCI U.S. REIT Index (RMZ). Armada Hoffler Properties Announces Its Fourth Quarter 2016 Cash Dividend. Armada Hoffler Properties Reports Third Quarter 2016 Results. S&P Global Market Intelligence. TERMS AND CONDITIONS OF USE. These Terms of Use are the entire agreement betwee...